Sunitinib and Atrial Trabeculae Contractility (SCAR)
The Influence of Sunitinib on Contractility of Human Atrial Trabeculae
Rationale:
Recently, sunitinib (a tyrosine kinase inhibitor that is used for treatment of metastatic renal carcinoma and gastrointestinal stroma tumors) has been associated with development of heart failure, possibly by off-target inhibition of AMP-protein kinase. The investigators hypothesize that sunitinib reduces the contractile ability of myocardium and the tolerance against ischemia-reperfusion and that activators of AMP-protein kinase such as atorvastatin and AICAR reverse this unwanted effect of sunitinib.
Objectives:
The primary objective of the study is to investigate the effect of sunitinib on ex-vivo atrial contractile force in absence and presence of ischemia-reperfusion.
A secondary objective is to explore if atorvastatin or AICAR prevent sunitinib-induced deterioration of contractile function of human atrial trabeculas. Study design: Lab
研究概览
详细说明
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Nijmegen、荷兰、6500HB
- Radboud University Nijmegen Medical Centre
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Cardiac surgery with extracorporal circulation
Exclusion Criteria:
- Use of oral antiarrhythmics
- theophylline use
- Use of sulfonylureas
- Atrial arrythmias
- Right ventricular failure
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
With/without sunitinib
Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution.
Both will be stimulated to contraction during 200 minutes.
|
|
With/without sunitinib IP
Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution.
Both will be stimulated to contraction and ischemia/reperfusion
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Force
大体时间：200 minutes
|
The developed force in ex vivo atrial trabeculae during standardized stimulation.
|
200 minutes
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Speed
大体时间：200 minutes
|
The difference in averaged maximal speed of tension reduction during relaxation between two trabeculae
|
200 minutes
|
|
Maximal Speed
大体时间：210 minutes
|
The difference in averaged maximal speed of tension development during contraction between two trabeculae.
|
210 minutes
|
合作者和调查者
调查人员
- 首席研究员：G. A. Rongen、Radboud University Medical Center
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.